CD8+ T cells are considered the key antitumor effector cells, and we observed a negative correlation between the expression level of ENTPD2 and the number of tumor-infiltrating CD8+ T cells in colon cancer patients and in mouse models. This evidence concerns the gene CD8A and neoplasm.